Onkologie. 2014:8(5):236-238

Metastatický karcinom ledviny - 2. linie léčby

MUDr. Hana Študentová
Onkologická klinika, Fakultní nemocnice, Olomouc

Published: October 16, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Študentová H. Metastatický karcinom ledviny - 2. linie léčby. Onkologie. 2014;8(5):236-238.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378 (9807): 1931-9. Go to original source... Go to PubMed...
    2. Michel MS, et al. ASCO-GU Symposium, January 30- February 1, 2014, San Francisco, CA, Abstract 393.
    3. Motzer RJ, Escudier B, Oudars S, et al. Phase 3 trial of everolimus for metastatis renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2012; 116: 4256-4265. Go to original source... Go to PubMed...
    4. Motzer RJ, Barrios CH, Kim TM, et al. Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2014 Sep 1;32 (25): 2765-72. Go to original source... Go to PubMed...
    5. Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014 Mar 10;32 (8): 760-7. Go to original source... Go to PubMed...
    6. Powles T, et al. ASCO Symposium, May 30 - June 3, 2014, Chicago. IL, USA, abstract 4525.
    7. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11; 356 (2): 125-34. Go to original source... Go to PubMed...
    8. Iacovelli R, Carteni G, Sternberg CN, et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. Eur J Cancer 2013; 49: 2134-42. Go to original source... Go to PubMed...
    9. Busch J, Seidel C, Erber B, et al. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma. Eur Urol 2013; 64: 62-70. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.